Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthSource vs Mevo Health

By GLP-1 ScorecardUpdated

HealthSource
Site position #105

Higher grade

Mevo Health
Site position #371

Lower grade

Score comparison

HealthSource has the higher recorded score — 71.2/100 to 60.2/100.

HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHealthSource +10
66
56
Dose & formulationEven
83
83
Clinical oversightHealthSource +13
80
67
Labs & monitoringHealthSource +2
54
52
FulfillmentHealthSource +23
80
57
Contract termsHealthSource +35
55
20
HealthSource · top barMevo Health · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricHealthSourceMevo Health
WeighScore71.2/10060.2/100
GradeCC
Site position#105#371
Semaglutide$199/mo (all doses, compounded)$199/mo (all doses, compounded)
Tirzepatide$299/mo (all doses, compounded)$259/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
HealthSource

Site position #105 · C

Strengths

  • Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
  • 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
  • Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
  • Subscription auto-refund if monthly reassessment is not completed
  • Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping

What to consider

  • No physician names or clinical leadership disclosed on public pages
  • No LegitScript certification found
  • 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
  • Labs not mentioned on any product page — baseline bloodwork protocol unknown
  • WooCommerce e-commerce storefront may feel more transactional than clinical
Mevo Health

Site position #371 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

What to consider

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard